原发性肝癌系统性化疗

    [1] Schwartz JD, Schwartz M, Mandeli J, et al. Neoadjuvant and adjuvant therapy for respectable hepatocellular carcinoma: review of the randomized clinical trials. Lancet Oncol, 2002, 3(10):593-603. 
 
    [2] Sun W, Sonnad S, Furth E, et al. Adjuvant chemotherapy in patients with hepatocellular carcinoma after orthotopic liver transplantation. Proc Am Soc Clin Oncol, 2005, Abstract 4126.

    [3] Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer, 1988,62(3):479-483.

    [4] Ishikawa T, Ichida T, Sugitani S, et al. Improved survival with oral administration of enteric-coated tegafur/ uracil for advanced stage IVA hepatocellular carinoma. J Gastroenterol Hepatol, 2001,16(4):452-459.

    [5] Vogel CL, Bayley AC, Brooker RJ, et al. A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer, 1977, 39(5): 1923-1929.

    [6] Hong RL, Tseng YL.A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol, 2003, 51(5): 433-438.

    [7] Valle JW, Dangoor A, Beech J, et al. Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin(PLD): results of a phase II study. Br J Cancer, 2005, 92(4): 628-630.

    [8] Jurgen P, Ivan Z, Wolfgang S, et al. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy, 2001,47(5):359-365.

    [9] Tumolo S, Toffoli G, Bearz A, et al. Oral idarubicin (IDA) for the treatment of hepatocellular carcinoma. Proc Am Soc Clin Oncol, 2002, Abstract 635.

    [10] Yoshida T, Okazaki N, Ohkura H, et al. Phase II trial of mitroxantrone in patients with hepatocellular carcinoma. Eur J Cancer Clin Oncol, 1988,24(12):1897-1898.

    [11] Tetef M, Doroshow J, Akman S, et al. 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest, 1995,13(5):460-463.

    [12] Porta C, Moroni M, Nastasi G, et al. 5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. Oncology, 1995, 52(6):487-491.

    [13] Shiraishi K, Kubo Y, Majima Y, et al. Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma. Gan To Kagaku Ryoho, 1984, 11(11):2348-2355.

    [14] Lencioni M, Falcone A, Allegrini G, et al. Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study. Oncology, 2000, 59(3):204-209.

    [15] Yehuda Z, Manal M, Alvaro A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer, 2004, 101(3):578-586.

    [16] Okada S, Okazaki N, Nose H, et al. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology, 1993, 50(1):22-26.

    [17] Yen Y, Doroshow J, Leong L, et al. Phase II study of oxaliplatin in patients with unresectable, metastatic or recurrent hepatocellular cancer. Proc Am Soc Clin Oncol, 2004, Abstract 4169.

    [18] O\'Reilly EM, Stuart KE, Sanz-Altamira PM, et al. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer, 2001, 91(1):101-105.

    [19] Yehuda ZP, Rowinsky E, O\'Reilly EM, et al. Phase II trial of DX-8951f (exatecan mesylate) in hepatocellular carcinoma (HCC): a final analysis. Proc Am Soc Clin Oncol, 2002, Abstract 555.

    [20] Yang TS, Lin YC, Chen JS, et al. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer, 2000, 89(5):750-756.

    [21] Strumberg D, Erhard J, Harstrick A, et al. Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma. Eur J Cancer, 1998,34(8):1290-1292.

    [22] Chao Y, Chan WK, Birkhofer MJ, et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer, 1998, 78(1):34-39.

    [23] Posey J, Johnson P, Mok T, et al. Results of a phase 2/3 open-label, randomized trial of T138067 verses doxorubicin (DOX) in chemotherapy-naive, unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol, 2005, Abstract 4035.

    [24] Stuart K, Tessitore J, Rudy J, et al. A phase II of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma. Cancer, 1999, 86(3):410-414.

    [25] Gallo J. Nolatrexed dihydrochloride vs. doxorubicin, a clinical update of a multi-center randomized phase II study in ethnic Chinese subjects with unresectable or metastatic HCC. Proc Am Soc Clin Oncol, 2004, Abstract 4262.

    [26] Cheng AN, Chen YC, Yeh KH, et al. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer, 1996, 77(5):872-877.

    [27] Nowak AK, Stockler MR, Chow PK, et al. Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review. Cancer, 2005, 103(7)1408-1414.

    [28] Qian Jun, Qin Shukui, He Zeming, et al. Arsenic trioxide in the treatment of advanced primary liver and gallbladder cancer. Chinese Journal of Oncology, 2001,23(6):487-489.

    [29] Lee J, Park JO, Kim WS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol, 2004, 54(5):385-390.

    [30] Tanioka H, Tsuji A, Morita S, et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res, 2003, 23(2C):1891-1897.

    [31] Ikeda M, Okusaka T, Ueno H, et al. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer, 2005,103(4):756-762.

    [32] Boucher E, Coubinais S, Brissot P, et al. Treatment of hepatocellular carcinoma with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol, 2002, 50(4):305-308.

    [33] Ikeda M, Okusaka T, Ueno H, et al. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer, 2005, 103(4): 756-762.

    [34] Lai CL, Lan JY, Wu PC, et al. Recombinant interferon-alpha inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology, 1993, 17(3) :389-394.

    [35] Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology, 2000, 31(1):54-58.

    [36] Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer, 2002,94(2):421-7.

    [37] Shin D, Lee SI, Park J, et al. Systemic chemotherapy with capecitabine, doxorubicin and cisplatin for metastatic hepatocellular carcinoma. Proc Am Soc Clin Oncol, 2005, Abstract 4177.

    [38] Yang TS, Wang CH, Hsieh RK, et al. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial. Ann Oncol, 2002, 13(11):1771-1778.

    [39] Yang TS, Chang WC, Lin YC, et al. A phase II study of gemcitabine and cisplatin for patients with advanced hepatocellular carcinoma. Proc Am Soc Clin Oncol, 2003, Abstract 1351.

    [40] Qin SK, Cao MR, Qian J, et al. Clinical study of FOLFOX regimen for the patients with advanced hepatocellular carcinoma. Chinese Clinical Oncology, 2005, 10(1):58-60.

    [41] Frustaci S, Bearz A, Basso B, et al. Efficacy of oxaliplatin and 5-fluorouracil in hepatocarcimoma. Proc Am Soc Clin Oncol, 2003, Abstract 1346.

    [42] Boige V, Raoul JL, Pignon JP, et al. Preliminary results of capecitabine-oxaliplatin (XELOX) in hepatocellular carcinoma (HCC) . Proc Am Soc Clin Oncol, 2005, Abstract 4128.

    [43] Taieb J, Mansourbakht T, Ducreux M, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma (AHCC) : Results of a phase II study. Proc Am Soc Clin Oncol, 2004, Abstract 4086.